Carlsmed, Inc. (CARL) Stock Forecast
CARL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $19.40 average of analyst targets
- Upside to target
- +44.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.41
- 52-week range
- $8.83 – $16.99
CARL analyst ratings
5 analystsNumber of analysts at each rating.
CARL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CARL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.41 | −$0.36 | −$0.37 | −4.6% | 2 |
| Current fiscal year (2026) | −$1.41 | −$1.45 | −$1.37 | −$1.97 | +28.3% | 2 |
| Next fiscal year (2027) | −$1.38 | −$1.46 | −$1.30 | −$1.41 | +2.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CARL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $19.2M | $18.4M | $19.6M | +46.6% | 5 |
| Current fiscal year (2026) | $76.7M | $76.0M | $77.0M | +51.9% | 5 |
| Next fiscal year (2027) | $108.1M | $101.7M | $115.6M | +40.9% | 5 |
CARL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CARL revenue: reported and forecast
CARL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.40 | −$0.40 | −$0.40 | −$0.39 | −2.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.47 | −$1.47 | −$1.47 | −$1.47 | −$1.41 | −3.8% | 1 up · 1 down |
| Next fiscal year (2027) | −$1.44 | −$1.44 | −$1.44 | −$1.44 | −$1.38 | −3.8% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CARL earnings surprises
Reported EPS vs the consensus estimate for the last 6 quarters; CARL beat in 4 of 6.
What analysts expect from CARL
5 analysts cover Carlsmed; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.40, 44.7% above the latest close of $13.41. Analysts expect earnings of −$1.41 per share for 2026, +28.3% from a year earlier. For 2027 the average estimate is −$1.38 per share on revenue of $108.1 million. Carlsmed beat the EPS estimate in 4 of the last 6 quarters.
Related: CARL income statement, CARL key metrics, CARL chart. See the CARL stock overview for the latest quote and news.
CARL forecast FAQ
What is Carlsmed's price target?
The average analyst price target for Carlsmed is $19.40, 44.7% above the latest close of $13.41.
Is Carlsmed a buy, hold or sell?
Of 5 analysts covering Carlsmed, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Carlsmed's EPS forecast?
Analysts forecast −$1.41 per share for 2026 (range −$1.45 to −$1.37); for 2027 the estimate is −$1.38.
What is Carlsmed's revenue forecast?
The average revenue estimate for 2026 is $76.7 million, growth of 51.9%; for 2027 it is $108.1 million.
When does Carlsmed report earnings?
Carlsmed is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.41.
Does Carlsmed usually beat earnings estimates?
Carlsmed reported EPS at or above the analyst estimate in 4 of the last 6 quarters.